<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0011009'>Acute</z:hpo>, short-term <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> enhances high shear stress-induced platelet activation in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Several observations suggest that platelets in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are resistant to inhibition by aspirin </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to assess comparatively the effect of aspirin, a nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>-donating agent (NCX 4016), their combination, or placebo on platelet activation induced by <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: In a double-blind, placebo-controlled, randomized trial, 40 type 2 diabetic patients were allocated to 100 mg aspirin once daily, 800 mg NCX 4016 b.i.d., both of them, or placebo for 15 days </plain></SENT>
<SENT sid="4" pm="."><plain>On day 15, 1 h after the morning dose, a 4-h hyperglycemic clamp (plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> 13.9 mmol/l) was performed, and blood samples were collected before and immediately after it for platelet activation and cyclooxygenase-1 (COX-1) inhibition studies </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> enhanced shear stress-induced platelet activation in placebo-treated patients (basal closure time 63 +/- 7.1 s, after <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> 49.5 +/- 1.4 s, -13.5 +/- 6.3 s, P &lt; 0.048) </plain></SENT>
<SENT sid="6" pm="."><plain>Pretreatment with aspirin, despite full inhibition of platelet COX-1, did not prevent it (-12.7 +/- 6.9 s, NS vs. placebo) </plain></SENT>
<SENT sid="7" pm="."><plain>On the contrary, pretreatment with the NO donor NCX 4016, alone or in combination with aspirin, suppressed platelet activation induced by <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (NCX 4016 +10.5 +/- 8.3 s; NCX 4016 plus aspirin: +12.0 +/- 10.7 s, P &lt; 0.05 vs. placebo for both) </plain></SENT>
<SENT sid="8" pm="."><plain>Other parameters of shear stress-dependent platelet activation were also more inhibited by NCX 4016 than by aspirin, despite lesser inhibition of COX-1 </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced enhancement of platelet activation is resistant to aspirin; a NO-donating agent suppresses it </plain></SENT>
<SENT sid="10" pm="."><plain>Therapeutic approaches aiming at a wider platelet inhibitory action than that exerted by aspirin may prove useful in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>